1 minute read

MEDICAL ONCOLOGY

Next Article
RADIATION MEDICINE

RADIATION MEDICINE

Abbrev. Title

Protocol Title

849-010 KRYSTAL-10 Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation

849-012 KRYSTAL-12 A Randomized Phase 3 Study of MRTX849 versus Docetaxel in Patients with Previously Treated Non-Small Cell Lung Cancer with KRAS G12C Mutation

CELC-G-301 VIKTORIA-1 A Phase 3, Open-Label, Randomized, Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive, HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy

D9670C00001 DESTINYBreast06 A Phase 3, Randomized, Multi-center, Open-label Study of Trastuzumab Deruxtecan (T-DXd) Versus Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Breast Cancer Patients Whose Disease H as Progressed on Endocrine Therapy in the Metastatic Setting

DS1602-A-U301 TROPION-LUNG01

Phase 3 Randomized Study of DS-1062A versus Docetaxel in Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer Without Actionable Genomic Alterations

HERTHENA–Lung02 A Phase 3, Randomized, Open-label Study of Patritumab Deruxtecan Versus PlatinumBased Chemotherapy in Metastatic or Locally Advanced Epidermal Growth Factor Receptor-Mutated (EGFRm) Non-Small Cell Lung Cancer (NSCLC) After Failure of EGFR Tyrosine Kinase Inhibitor (TKI) Therapy

R1979-ONC-1625 ELM-2 An Open-Label Study to Assess the Anti-Tumour Activity and Safety of REGN1979, an Anti CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed or Refractory B-cell NonHodgkin Lymphoma

XL092-303 STELLAR-303 A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer

This article is from: